{"id":2807,"date":"2018-07-20T15:38:18","date_gmt":"2018-07-20T10:08:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2807"},"modified":"2025-05-12T15:26:04","modified_gmt":"2025-05-12T09:56:04","slug":"acute-lymphoblastic-leukemia","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia","title":{"rendered":"Snippet : Acute lymphoblastic leukemia"},"content":{"rendered":"<p style=\"background: white;\"><span style=\"font-size: 13.0pt; font-family: 'Times','serif'; color: #222222; letter-spacing: .15pt; background: white;\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-lymphoblastic-leukemia-all-market\">Acute lymphoblastic leukemia<\/a> (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from solid tumours, metastases of ALL seldom involve the parenchyma but are isolated to the leptomeninges, which is an infrequent site for carcinomatous invasion. Although metastasis to the CNS occurs across all subtypes of Acute lymphoblastic leukemia, a unifying mechanism for invasion has not yet been determined. The basement membrane of these bridging vessels is enriched in laminin. The laminin receptor \u03b16 integrin is expressed in most cases of ALL. Mice with Acute lymphoblastic leukemia xenografts were treated with either a PI3K\u03b4 inhibitor, which decreased \u03b16 integrin expression on ALL cells. Our data suggest that \u03b16 integrin expression, which is common in ALL, allows cells to use neural migratory pathways to invade the CNS.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from solid tumours, metastases of ALL seldom involve the parenchyma but are isolated to the leptomeninges, which is an infrequent site for carcinomatous invasion. Although metastasis to the CNS occurs across all subtypes of Acute lymphoblastic leukemia, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2744,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[17564,12079],"industry":[17225],"therapeutic_areas":[17228,17234],"class_list":["post-2807","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-acute-lymphoblastic-leukemia","tag-all","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Snippet : Acute lymphoblastic leukemia - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from ..........\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Snippet : Acute lymphoblastic leukemia - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from ..........\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-07-20T10:08:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T09:56:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/03\/09021710\/CANCR.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"700\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Snippet : Acute lymphoblastic leukemia - DelveInsight Business Research","description":"Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from ..........","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia","og_locale":"en_US","og_type":"article","og_title":"Snippet : Acute lymphoblastic leukemia - DelveInsight Business Research","og_description":"Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from ..........","og_url":"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-07-20T10:08:18+00:00","article_modified_time":"2025-05-12T09:56:04+00:00","og_image":[{"width":700,"height":400,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/03\/09021710\/CANCR.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia","url":"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia","name":"Snippet : Acute lymphoblastic leukemia - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/03\/09021710\/CANCR.jpg","datePublished":"2018-07-20T10:08:18+00:00","dateModified":"2025-05-12T09:56:04+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Acute lymphoblastic leukemia (ALL) has a marked propensity to metastasize to the CNS. In contrast to brain metastases from ..........","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/acute-lymphoblastic-leukemia#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/03\/09021710\/CANCR.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/03\/09021710\/CANCR.jpg","width":700,"height":400,"caption":"Acute lymphoblastic leukemia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/03\/09021710\/CANCR-300x171.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Acute Lymphoblastic Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ALL<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Lymphoblastic Leukemia<\/span>","<span class=\"advgb-post-tax-term\">ALL<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Jul 20, 2018","modified":"Updated on May 12, 2025"},"absolute_dates_time":{"created":"Posted on Jul 20, 2018 3:38 pm","modified":"Updated on May 12, 2025 3:26 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2807"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2807\/revisions"}],"predecessor-version":[{"id":32081,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2807\/revisions\/32081"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2744"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2807"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2807"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}